NCT03307785 2025-11-25
Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042
Tesaro, Inc.
Phase 1 Completed
Tesaro, Inc.
Bristol-Myers Squibb
Peregrine Pharmaceuticals
Intergroupe Francophone de Cancerologie Thoracique
Asan Medical Center
University of Saskatchewan
West Japan Thoracic Oncology Group